SEC Form 4 · accession 0001177648-18-000030
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay R. Luly
Officer — President and CEO · Director
Period of report
Jul 5, 2018
Accepted (ET)
Jul 9, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 5, 2018 | S | 2,977 | $123.8051 | D | 625,049 | D | |
| Common StockF3 | Jul 6, 2018 | S | 12,622 | $124.264 | D | 612,427 | D | |
| Common StockF4 | Jul 6, 2018 | S | 7,538 | $125.2673 | D | 604,889 | D | |
| Common StockF5 | Jul 6, 2018 | S | 7,738 | $126.3618 | D | 597,151 | D | |
| Common StockF6 | Jul 6, 2018 | S | 4,125 | $127.1222 | D | 593,026 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.02, inclusive.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.74, inclusive.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $125.79, inclusive.
- F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.79, inclusive.
- F6The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.80 to $127.52, inclusive.